Table 1.
Characteristics of HIV-infected individuals with and without COVID-19 diagnosis
| HIV-infected individuals with COVID-19 (n=51) | HIV-infected individuals without COVID-19 (n=1288) | p value | ||
|---|---|---|---|---|
| Age, years | .. | .. | 0·915 | |
| Mean (SD) | 53·3 (9·5) | 53·5 (10·2) | .. | |
| Range | 31–75 | 23–91 | .. | |
| Gender | .. | .. | 0·240 | |
| Female | 8 (16%) | 299 (23%) | .. | |
| Male | 43 (84%) | 989 (77%) | .. | |
| Race | .. | .. | 0·163 | |
| White | 45 (88%) | 1155 (90%) | .. | |
| Black | 0 | 31 (2%) | .. | |
| Asian | 1 (2%) | 4 (<1%) | .. | |
| Latin American | 5 (10%) | 98 (8%) | .. | |
| Body-mass index, kg/m2 | 25·5 (22·1–28·0) | 23·7 (21·5–26·0) | 0·021 | |
| <18·5 | 2 (4%) | 32 (2%) | 0·715 | |
| 18·5–24·9 | 22 (43%) | 518 (40%) | 0·019 | |
| ≥25·0 | 27 (53%) | 311 (24%) | 0·024 | |
| Time since HIV infection diagnosis, years | 19·5 (9·3–28·6) | 22·6 (13·5–28·7) | 0·186 | |
| Nadir CD4 count, cells per μL | 224 (120–437) | 212 (91–330) | 0·182 | |
| <200 | 24 (47%) | 597 (46%) | 1·000 | |
| 200–499 | 21 (41%) | 610 (47%) | 0·396 | |
| ≥500 | 6 (12%) | 81 (6%) | 0·138 | |
| Antiretroviral therapy | ||||
| Any | 51 (100%) | 1284 (>99%) | 1·000 | |
| Protease inhibitors | 11 (22%) | 175 (14%) | 0·578 | |
| NNRTI | 8 (16%) | 269 (21%) | 0·054 | |
| INSTI | 41 (80%) | 707 (55%) | 0·410 | |
| Tenofovir (TAF or TDF) | 37 (73%) | 487 (38%) | 0·0036 | |
| Comorbidities | ||||
| Any | 32 (63%) | 495 (38%) | 0·00059 | |
| Hypertension | 18 (35%) | 102 (8%) | <0·0001 | |
| Diabetes | 7 (14%) | 38 (3%) | 0·0011 | |
| Chronic kidney disease | 6 (12%) | 17 (1%) | 0·00014 | |
| Chronic liver disease | 24 (47%) | 419 (33%) | 0·034 | |
Data are n (%) or median (IQR) unless otherwise specified. INSTI=integrase strand transfer inhibitor. NNRTI=non-nucleoside reverse transcriptase inhibitor. TAF=tenofovir alafenamide. TDF=tenofovir disoproxil fumarate.